Prediction of Axillary Lymph Node Metastasis Status in Breast Cancer Based on PET/CT Radiomics
- Disease/Condition
- Breast Neoplasms
- Drug/Device/Intervention
- Radiomics
- Study type
- Observational
- Intervention type
- other
- Primary sponsor
- First Affiliated Hospital Xi'an Jiaotong University
- Phase
- N/A
- Start date
- May 10, 2023
- End date
- Dec 01, 2024
- Enrollment
- 100 participants
Radiomics score
Patients with suspected breast cancer undergoing PET/CT at our hospital. The PET/CT center's
 chief physician and senior attending physician reviewed the films together and disagreement,
 if any, was resolved by consensus. The lesion was visually identified. A 3D region of
 interest(ROI) of the lesion was automatically outlined using the 40% threshold method, and
 PET metabolic parameters were measured . Breast lesions with radionuclide concentrations
 greater than those in normal breast tissue are considered to be breast cancer lesions, while
 lymph nodes with radionuclide concentrations greater than those in muscle tissue are
 considered to be metastatic lymph nodes.
 
 Image segmentation: Image segmentation was performed using ITK-SNAP software (4) (version
 3.6.0, http://www.itksnap.org/), Brush Style: circular, Brush Size: 10, Brush Options: 3D.
 The entire tumor volume was outlined on the PET image as ROI for segmentation.
 
 An open source Python package (PyRadiomics version 3.0.1(5)) was used to extract the
 radiomics features from the ROI.
 
 Univariate and multivariate binary logistic regressions were used to construct model for
 predicting lymph node metastasis in breast cancer.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05826197
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05826197 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital Xi'an Jiaotong University and is currently Not yet recruiting. The study focuses on Breast Neoplasms. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.